The Derms on Drugs bring in a heavy hitter straight out of silicon valley to talk AI and the future of dermatology. Dr. Faranak Kamangar is a Board Certified Dermatologist who founded, built and continues to improve DermGPT - a derm specific LLM that just outperformed ChatGPT in a head-to-head contest judged by dermatologists! As usual, we'll answer the questions you didn't know you had (well, maybe you knew you had some of these):

• Is AI going to make our lives easier or is it going to replace us?
• How good is AI at answering patient questions?
• Will patients accept "AI Providers"?
• How can you start levering AI now to make your life better?
• What AI tools are out there to start using right now?
• Are AI scribes all that great?

The Derms on Drugs give the definitive answer to the age old question: What came first, the chicken or the egg? You'll have to listen to find out.

• What's a Mazotti Reaction and why do you care?

• How do JAK inhibitors compare to dupilumab for treating prurigo nodularis?
• What's a cheap, easy, safe, effective treatment for palmoplantar pustulosis?
• Can a steroid nasal spray help for Chronic Spontaneous Urticaria?
• Do biologics reduce infection risk in AD more than JAK Inhibitors and why?
• How does superficial radiation therapy compare to Mohs for skin cancer?
• Dermal hyperpigmentation is impossible to treat - can isotretinoin help?
• Cheilitis drives derms and patients nuts - what's the new, cheap, easy way to help?

Get ready for a no-nonsense tour-de-force of practical application in the latest derm literature. Pipeline drugs, new approvals, brand names, generics—and HS data you’re better off ignoring (we’ll tell you why).

In this episode:

· Leqselvi: the newest JAK for alopecia areata—actually different, or more of the same?

· HS & spondyloarthritis: are you screening… should you be?

· JAKs and the heart: are all cardiovascular risks created equal?

· “2/3 HS remission” headlines: why this data shouldn’t change your practice

· Tirbanibulin + cryo for AKs: combo win or marketing math?

· Hydrochlorothiazide & skin cancer: do you really need that conversation?

· Oral minoxidil + Olumiant: synergy or wishful thinking in AA?

· OX40/OX40L blockers: exciting pathway—new hope or new hype?

Fast. Practical. Slightly skeptical (for good reason).

If you prescribe, counsel, or roll your eyes at bad data—this one’s for you.